Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 16, 2015BloodOpen Access

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

SHShernan G. HoltanRoswell Park Comprehensive Cancer CenterTDTodd E. DeForUniversity of MinnesotaALAleksandr LazaryanMoffitt Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Holtan et al. (2015) studied this question.

synapsesocial.com/papers/69faac18e63148787cd2e8c3https://doi.org/10.1182/blood-2014-10-609032
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Use of composite endpoints in clinical trials2014 · 75 citations
  2. 2Ex Vivo T Cell–Depleted versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission2013 · 100 citations
  3. 3Estimation of Variance in Cox's Regression Model with Shared Gamma Frailties1997 · 135 citations
  4. 4Nonparametric Estimation from Incomplete Observations1958 · 39,556 citations
  5. 5Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT2005 · 2,984 citations